Introduction
There are many published articles and reviews concerning renal artery stenosis. [1] [2] [3] [4] This paper is not a review. This paper represents the collective view of British hypertension clinicians as a 2007 consensus statement on the investigation and management of individuals with renal artery stenosis in current UK practice. It is a summary of the special session held to address this issue at the September 2006 British Hypertension Society annual conference in Cambridge. The contributing panel and BHS members are listed at the end of the paper.
Renal artery stenosis occurs in two distinct formsfibromuscular dysplasia in children and young adults; and atherosclerotic stenosis in older individuals, usually with coexisting widespread atheroma. Fibromuscular dysplasia is usually successfully treated by balloon angioplasty, although the second case below illustrates graphically the risk of post-procedural hypotension, which will be discussed later.
Atherosclerotic renal artery stenosis is common, can be unilateral or bilateral and is found in up to 5% of hypertensive patients. It seems intuitive that relief of a severe stenosis ought to protect the affected kidney(s) and improve blood pressure (BP) control. Flow-limiting stenosis increases renin release, causes salt and water retention and raises BP. Severe stenosis leads to ischaemia, loss of functioning nephrons and eventually organ failure. Yet, there exists no robust data from randomized trials that angioplasty, or even surgery, clearly improves longterm outcome, BP, preservation of renal function or overall survival. This position statement collates available evidence and expert opinion to provide what we believe to be the current understanding and recommendations for treatment of atherosclerotic renal artery stenosis.
Available data from randomized trials
There are three studies where patients were randomized to percutaneous intervention (angioplasty7 stenting) or medical therapy. [5] [6] [7] End points were prevention of decline in renal function, improvement in BP control or both. A total of 210 patients were enrolled in the three trials, so it is unsurprising that no definite conclusions can be drawn. No clear benefits were shown in meta-analysis, 8 yet most practising clinicians have patients in whom angioplasty has brought about major long-term success. So why did the trials fail?
The pioneering, earliest trial, led by Webster 5 from Aberdeen, randomized 55 patients to angioplasty without stenting, or medical therapy, and showed no overall benefit, with a complication rate of 20% among the angioplasty group. The second randomized study by Plouin et al. 6 studied 49 individuals and again found no overall benefit. Stents were only used in two patients. The largest trial to date, the Dutch Renal Artery Stenosis Intervention Cooperative Study (DRASTIC study), led by van Jaarsveld, 7 randomized 106 patients and is described in more detail. Patients were mostly revascularized with balloon angioplasty alone, with stenting only when angioplasty failed. Renal artery occlusion occurred in 16% of the medically treated group but in none of the angioplasty patients, suggesting at least anatomical superiority of angioplasty, but this was not analysed as an end point. Furthermore, 44% of the patients assigned to the medical therapy group continued to have poorly controlled BP at 3 months and underwent balloon angioplasty. Analysis on an intention-to-treat basis excluded this high crossover rate. Thus in the Dutch study, medical therapy failed in at least 60% of patients assigned to medical treatment of renal artery stenosis. There was a trend toward better BP control in the revascularization group, yet the Dutch study was not sufficiently large to detect whether this difference was significant.
Apart from the small numbers, we believe the principal reason these trials failed to demonstrate clear benefit is that the diagnosis of renal artery stenosis was made from anatomic studies, with little or no assessment of flow limitation. Patients were randomized if there was a 450% stenosis. Yet, when comparing this with the coronary circulation, it is known from positron-emission tomography (PET) and intracoronary Doppler studies in the coronary arteries that a stenosis of 470% is required to substantially affect coronary blood flow. 9 So it is likely that many patients will have been included in the renal studies where there was no limitation to flow, so angioplasty would offer only risk, with no benefit. But at the time these trials were performed, reliable techniques for routine assessment of renal blood flow through stenoses were not available. Measurement of pressure change by catheter withdrawal across the lesion was and is still used, but is unreliable since the catheter itself may provide significant obstruction. Better magnetic resonance imaging (MRI) angiography may answer this question, but this has not been tested in a randomized trial.
Below are summarized the two case presentations from the 2006 British Hypertension Society annual conference, which illustrate the complexity of this condition.
Case 1
A 63-year-old University Professor had developed hypertension 10 years ago. After 6 years, he was on a combination of lisinopril, bisoprolol, amlodipine and bendroflumethiazide. He discontinued all therapy and presented 3 years later with dyspnoea on exertion; BP was 240/120 mm Hg. His medication was reintroduced as before. Electrocardiogram (ECG) showed left ventricular hypertrophy (LVH). Chest X-ray was normal. He was a non-smoker and drank one bottle of wine per day. Four months later, he had a 4-day episode of paraesthesiae in his right arm, leg and face, which resolved. At the local Neurovascular Clinic, BP was 145/95 mm Hg. Carotid duplex scans were normal, cholesterol 6.5 mmol/l and he was started on aspirin and statin therapy. He was also referred to the Hypertension Clinic, with BP then 165/96 mm Hg. Lisinopril was changed to candesartan 16 mg. Two months later, BP was 148/88 mm Hg; tests for pheochromocytoma were negative. Plasma creatinine was 100 mmol/l and plasma renin was markedly elevated at 361 ng/ ml. Echocardiography showed normal left ventricular size and function, including normal diastolic function. Spironolactone (50 mg) was added to his therapy and MRI renal angiography was performed. The left kidney was slightly smaller than the right, and each kidney had a single main renal artery. There were moderately severe stenoses of the ostia of both renal arteries, more marked on the left. Urea, electrolytes and creatinine were normal.
Mercaptoacetyltriglycine (MAG 3 ) scan with captopril challenge revealed normal bilateral transit time. Relative function of the left kidney was 33%, and the right kidney 67%. Renal vein renin sampling showed levels of 411 mU/l from the left and 388 mU/l from the right kidney. The likely diagnosis was atherosclerotic ostial renal artery stenosis.
Intra-arterial angiography demonstrated a large pressure gradient at both ostia (70 mm Hg on the right and 100 mm Hg on the left). Bilateral 5 mm balloon dilatation reduced the gradients to 15 mm Hg bilaterally. BP following the procedure was 120/ 80 mm Hg. At follow-up, BP was 120/80 mm Hg on bisoprolol, amlodipine, bendroflumethiazide, candesartan and spironolactone. Creatinine was 109 and the plasma renin was 92. The spironolactone was discontinued. At his next review, he was feeling much better and could sustain strenuous walking with no symptoms.
The BP was better controlled overall since the procedure -a successful case of treatment of atherosclerotic bilateral renal artery stenosis in a 62-year-old man by balloon angioplasty.
Case 2
A 28-year-old female nursing student was referred with BP recordings averaging 160/90 mm Hg. She smoked 10 cigarettes per day, had a body mass index of 22 and a normal student alcohol intake. There was a family history of hypertension, with both mother and maternal grandmother diagnosed in their late 40s. She was commenced on atenolol 50 mg once daily with good effect but was referred to secondary care for ongoing management. The 24 hambulatory BP measurements carried out while on atenolol showed an average of 160/94 mm Hg. Echocardiography revealed a slightly thickened right ventricle but a normal left ventricle. She defaulted several times from clinic, and at her last clinic attendance her BP recording was 232/104 mm Hg. She stated that she was fully compliant with her therapy at this time. Amlodipine 5 mg was added. Magnetic resonance angiography (MRA) was performed that confirmed renal artery stenosis. Intraarterial angiography showed stenosis of the middle to distal thirds of the right renal artery. In association with this occlusion of the coeliac axis, an occlusion of the superior mesenteric artery and the right common iliac artery was found. Renal artery angioplasty was undertaken with good effect. However, 6 h after the procedure, she had a vasovagal episode. BP was 120/80 mm Hg. Two hours later, she became confused without specific neurological signs. Three hours later, she developed features of a right cerebrovascular accident, with left-sided facial droop, left-sided neglect and a mild left arm and left leg weakness grade 4 þ . The following morning, she had developed dysphasia. Computed tomography (CT) and MRI brain scans showed three infarcts in the area of the middle cerebral artery (MCA), thought to be consistent with a watershed infarct in the MCA territory. Subsequent MR angiography of the carotid vessels was normal, but intracranial angiography demonstrated sparse flow within the circle of Willis. There was also deficiency in the right anterior cerebral artery. The findings at this time were considered to represent diffuse intracerebral disease or possibly a vasculitis. Vasculitis tests had previously been negative.
Four days after angioplasty, she deteriorated further, required ventilation and was transferred to neurosurgery. CT showed marked extension of her cerebral infarct with considerable oedema. There was midline shift with depression of the right ventricle and contralateral dilatation, features consistent with a middle cerebral artery syndrome. She underwent urgent decompressive craniotomy. The patient stabilized with a left-sided spastic hemiparesis, severe dysphasia and frontal lobe signs. Currently, she can mobilize with an elbow crutch, dress and feed independently. BP is currently 141/ 90 mm Hg on atenolol.
Which patients are likely to have atherosclerotic renal artery stenosis?
Patients who present with accelerated or malignant phase hypertension, flash pulmonary oedema, unexplained renal impairment or hypertension whose renal function deteriorates with angiotensin-converting enzyme (ACE)/angiotensin receptor blocker (ARB) are well-known. Also, patients with established vascular disease and hypertension are likely to have atheromatous lesions, often ostial. The presence of an abdominal bruit is an important clinical sign. Thus, the indications of which patients are likely to have renal artery stenosis is reasonably clear.
What investigations should be carried out?
Anatomical tests Anatomical tests to define the presence and severity of stenosis and its effects are renal ultrasound, MRI renal angiography, CT angiography and direct intra-arterial digital subtraction angiography. Renal ultrasound will determine renal size and tissue consistency and Doppler studies can sometimes measure renal blood flow, but identification of significant stenosis is often inaccurate, because of difficulties in performing the examination due to an inability to align the ultrasound beam exactly in line with the renal artery. Without correct alignment of the Doppler ultrasound beam, flow velocities will be recorded incorrectly. In UK practice, ultrasound is most often used as a preliminary investigation and like US practice, has been largely superseded by MRI. 4 MRI scanning with 3D dynamic gadoliniumenhanced and 3D phase-contrast MRA techniques is now the most widely used investigation to study renal arteries in the United Kindom. Accurate anatomical detection of stenosis in the main renal arteries is very good, although accuracy is weaker within the smaller arterial branches. The main weakness of MRI is that stenoses may be over-or underestimated because of the limited number of planes that can be studied. The most modern MRI and CT equipment affords 3D reconstruction that may become valuable and standard practice in the near future. Little information is obtained regarding the functional significance of a stenosis, and this difficulty to identify a stenosis, relief of which might reverse adverse progression, underpins the uncertainty of diagnosis in this condition. CT angiography is of similar value, but carries a moderate radiation dose, and is usually reserved for patients who cannot tolerate or undergo MRI scanning. But MRI is not without risk itself. Recent reports have linked gadolinium-based contrast media with the development of nephrogenic systemic fibrosis. 10 This grave complication is usually seen in patients with moderate to severe renal impairment. More information is awaited.
Direct angiography with contrast injection into the renal arteries is rarely done as a stand-alone investigation, but is, of course, performed before insertion of guidewire and balloon or stent. Intraarterial Doppler flow wire studies have been performed within the renal arteries to determine the significance of the stenosis but perhaps surprisingly are not well-validated nor routine practice. Within the coronary circulation, this technique has been widely employed, using adenosine or dipyridamole to cause downstream vasodilatation which enables the functional significance of a stenosis to be determined accurately. 9 The lack of such a provocation test within the renal arterial bed may explain why angioplasty carried out purely on the visual assessment of stenosis may lead to dilatation of narrowed arteries which do not have a functional significance. Translesional pressure gradients are routinely measured, but their value is not certain in identifying a critical stenosis, since the catheter itself will obstruct flow to some extent. Papaverine, an endothelium-independent vasodilator, has been tried as a provocation test in the renal circulation but is not in routine clinical use in the UK. Indeed, intra-renal translesional pressure gradients have been disappointing in their ability to predict angioplasty success. 4 
Functional tests
Functional tests exist, aiming to define the significance of renal artery stenosis on renal function. In a patient on no antihypertensive therapy, peripheral renin levels may be raised, but if there is considerable salt and water retention from activation of the reninangiotensin-aldosterone cascade, renin levels may normalize. Thus, a raised peripheral renin level might indicate renal artery stenosis but a normal plasma renin concentration does not rule out significant renal artery stenosis. Direct sampling of renin levels within the renal veins is sometimes carried out but its use is not widespread. A substantial difference between the normal and the affected kidney can be a useful indicator in unilateral disease.
If plans for nephrectomy for a badly scarred kidney are being considered, the demonstration of a markedly elevated renin from the affected kidney may strengthen the case for surgical removal.
Diethylene triamine penta-acetic acid (DTPA) is established as an indicator of glomerular filtration. ACE inhibitors reduce glomerular filtration in renal artery stenosis by shunting blood through the glomerulus resulting from efferent arteriolar dilatation. 11 This principle is used in the captopril nuclear renogram. Administration of captopril before DTPA injection in an ACE-inhibitor-naïve individual will reduce glomerular filtration where there is renal artery stenosis. This technique is only useful for unilateral disease and, indeed, within the UK the captopril renogram is less employed since the advent of MRI angiography. Furthermore, patients on long-term ACE inhibitor therapy may have a false-negative Captopril renogram. Discontinuing ACE inhibitor therapy in a patient with poorly controlled hypertension may be considered to carry a risk, and physicians are often reluctant to do so. 4 A more recent development is to study renal plasma flow. 4 Captopril increases renal plasma flow without glomerular filtration -this phenomenon can be measured with technetium-labelled MAG 3 . This technique has not yet found its place in routine practice in the United Kindom, but shows promise as a more robust test of differential function.
More complex Doppler ultrasound methods have been proposed as a way of identifying kidneys that will respond favourably to angioplasty. The renal resistive index, a derived measurement of altered flow in nephrosclerotic kidneys, is calculated. Kidneys with high resistance may benefit less from angioplasty, since the kidney is too diseased to improve much with increased flow. 12 Perhaps an important and overlooked conclusion from this technique, not immediately clear from the published study, is that the resistive index in the contralateral, untreated kidney, may be an important predictor of success (G Roditi, personal communication).
Measurements of brain natriuretic peptide (BNP) may yet become valuable. BNP levels may be elevated in renal artery stenosis. Angiotensin II stimulates BNP production in the ventricular myocardium. BNP is well established as a 'rule-out' test for patients with heart failure, but its role in renal artery stenosis is yet to be fully defined. It has potential in defining the presence of a significant stenosis. 4 What techniques for renal artery dilatation should be employed?
Fibromuscular dysplasia
Younger patients found to have fibromuscular dysplasia usually respond well to balloon angioplasty. Only rarely is stent deployment required. Simple balloon angioplasty usually offers long-term resolution of the fibromuscular stenosis. There is little argument that renal artery angioplasty offers the best chance of long-term success.
Atherosclerotic renal artery stenosis
Stenosis is caused by atheroma either at the ostia or within the body of the renal artery. Stenoses can develop within branches but angioplasty of isolated lesions in branch arteries is unlikely to carry longterm major benefits, and has more risk of renal damage. Angioplasty of ostial lesions is much less straightforward than angioplasty in the main body of the artery, since stabilizing a stent within a dilated ostial lesion is more difficult. Aortic wall atheroma may be up to 1 cm thick. Stenting is now usually performed either directly delivered as the first intervention, or after initial balloon dilatation, and simple balloon angioplasty without stent insertion is much less frequently performed. Stents are usually bare metal rather than drug eluting; restenosis rates of less than 20% are described. Angioplasty is of course not without hazard. Procedural mortality is about 1-5% and major complications about 5-10%, related to femoral artery complications, haemorrhage, sepsis and embolization of atherosclerotic material to the kidney or the lower limbs. 11 Indeed, cholesterol embolization to the treated kidney is a serious complication. For reasons that are unclear, the kidney is much more susceptible to embolization and damage at the time of angioplasty than angioplasty in the native coronary circulation (coronary bypass vein grafts are a notable exception). The placing of filters downstream from the site of renal angioplasty is being assessed. Cholesterol embolization of the pelvis and lower limbs can occur, but is less frequent. A useful marker for patients with chronic renal failure who may be susceptible to cholesterol embolization is a raised eosinophil count. 13 Such individuals may have a chronic low-grade cholesterol embolization syndrome, and respond poorly to renal angioplasty. Direct damage to the aorta or iliacs is infrequent. Contrast nephropathy is also a potential risk.
Peri-procedural management
One of the key features, and illustrated vividly in case 2 above, but not described in the reviews, is medical management of the patient during the angioplasty period. During the few hours following renal artery dilatation, BP may fall substantially. It is therefore usual and indeed wise to discontinue antihypertensive therapy on the day of the procedure. Indeed, some physicians discontinue therapy 48 hours in advance, although most UK practice is to withhold on the day of angioplasty. Patients should be kept on bed rest for at least 6 hours following renal artery angioplasty since a marked postural drop can occur in the first few hours following the procedure. During the procedure it is usual to give intra-arterial glyceryl trinitrate (GTN) to reduce renal artery spasm, together with a bolus of heparin. The effects of the GTN wear off rapidly, and have no effect on later BP fluctuations.
Discussion
Renal artery angioplasty for older individuals with hypertension and renal artery stenosis remains a condition with no robust clinical trial evidence. The best data we have suggest a modest benefit in BP, and a decline in the progression to renal failure among patient with renal parenchymal disease and renal artery stenosis. It seems that once a kidney is chronically diseased, shrunken to less than 8.5 cm on ultrasound, then angioplasty offers no hope of restoration of function. 4 So what should we do? It seems intuitive that relief of a critical 99% stenosis must have benefit in the long term, yet the data are lacking. The major problem with the trials so far is that the hypothesis that a stenosis of 50% is sufficient to cause flow limitation is probably incorrect. It is likely that a stenosis of much greater severity is required to generate the renin, other mediators and hypertension from an affected kidney. A recent study from Ramos and colleagues 14 showed that when an arterial stenosis of 70% with a trans-lesion pressure gradient430 mm Hg was defined as the lower limit of significance, angioplasty offered a significant reduction in BP, with a modest increase in glomerular filtration rate. These data are from an observational study rather than a clinical trial but at least point the way towards the demonstration that relief of a severe stenosis may be of value.
There are data yet to come. In the UK and Australia, the Angioplasty and STent for Renal Artery Lesions (ASTRAL) trial has now completed its recruitment of 800 patients, to compare medical therapy with angioplasty7stent for patients with atherosclerotic renal artery stenosis (J Moss, AS-TRAL steering committee, personal communication; http://www.astral.bham.ac.uk). In this trial, the definition of stenosis in any degree is considered by the operator to be significant, usually 450% as defined by MRI scanning or direct angiography, and where the clinician is uncertain of the role of angioplasty. Importantly, the majority have a stenosis470%. The results will be stratified by degree of stenosis, as well as BP and renal function. The ASTRAL results are looked forward to with anticipation. One-year follow-up data should become available during 2008. However, there is unlikely to be a major early mortality benefit, since the trial has not been terminated before its planned conclusion. Long-term benefit is clearly crucial and will be forthcoming from this important trial.
In the United State, the 'Cardiovascular Outcomes in Renal Atherosclerotic Lesions' trial, the CORAL trial, has been set up to address the same issue. 15 In the CORAL trial, the definition of stenosis is narrowing of greater than 60%. We presume that the CORAL results will be stratified by degree of stenosis since it is our view that 60% stenosis might not be sufficient to define a haemodynamically significant lesion. The American CORAL trial has not yet closed to recruitment and results are not expected for some time.
In the meantime, what is the UK position? Which patients should be investigated is generally clear. How to investigate is less clear, since functional tests of renal insufficiency consequent on stenosis are not absolutely defined. Anatomical definition of a critical stenosis, at least 75%, will likely indicate an individual in whom angioplasty may offer real benefit. BP control may well be improved, and renal deterioration is likely to be reduced or slowed. Patients with the combination of flash pulmonary oedema and severe renal artery stenosis are also likely to benefit from intervention. Beyond this, we are much less certain, since angioplasty certainly carries serious risks with currently doubtful beneKey practice points: K Atherosclerotic renal artery stenosis is frequently found in individuals with hypertension and vascular disease. K Angioplasty for fibromuscular renal artery stenosis can be curative, but is not without risk. K Relief of critical stenosis can improve hypertension control and reduce progression of renal impairment. K Anatomic diagnosis is usually made by magnetic resonance (MR) or computed tomography (CT) angiography, but the severity can be overestimated. K Stenosis of 470% is probably important. The translesional pressure gradient is a poor predictor of severity. K Functional tests of stenosis severity remain of uncertain value. K Angioplasty is usually ineffective if a diseased kidney is shrunken to o8 cm length. fits. For patients in whom moderate stenosis, say 50-70%, is defined we could wait a year or so until ASTRAL reports.
